Purpose This study determined how the magnitude of change in positive subjective responses predicts clinical outcome in a treatment setting. Specifically, we attempted to define what constitutes a clinically important difference (CID) in subjective responses. Methods A 100-mm visual analog scale (VAS) measured subjective ratings of drug ''high,'' calculated via an anchorbased method with published data from participants receiving sustained-release naltrexone (NTX) and heroin in a laboratory setting. The data were then compared to clinical outcomes in a treatment trial with sustained-release naltrexone. A distribution-based method subsequently analyzed data from participants who received ALO-01 (extended-release morphine with sequestered NTX) to predict its abuse liability. Results Differences in ratings of drug high of approximately 10 mm on a 100-mm line were clinically significant. By extrapolation, CIDs were also found between crushed or intact ALO-01 and immediate-release morphine sulfate (IRMS). No CIDs were found between intact and crushed ALO-01. Conclusions From laboratory and treatment trial data involving naltrexone, calculation of CIDs in subjective ratings of high is possible. Consequently, crushing/swallowing or injecting ALO-01 produces clinically significantly less drug high than oral or intravenous morphine alone, suggesting that ALO-01 has lower abuse liability by those routes than morphine formulations.
clinical outcomes in a treatment trial with sustained-release naltrexone. A distribution-based method subsequently analyzed data from participants who received ALO-01 (extended-release morphine with sequestered NTX) to predict its abuse liability. Results Differences in ratings of drug high of approximately 10 mm on a 100-mm line were clinically significant. By extrapolation, CIDs were also found between crushed or intact ALO-01 and immediate-release morphine sulfate (IRMS) . No CIDs were found between intact and crushed ALO-01. Conclusions From laboratory and treatment trial data involving naltrexone, calculation of CIDs in subjective ratings of high is possible. Consequently, crushing/swallowing or injecting ALO-01 produces clinically significantly less drug high than oral or intravenous morphine alone, suggesting that ALO-01 has lower abuse liability by those routes than morphine formulations.
Keywords Analgesics Á Opioid Á Drug formulations Á Morphine Á Drug high Á Abuse liability [3] [4] [5] or distribution-based methods. An anchor, generally an objective measure (e.g., laboratory value, clinical diagnosis), has some relationship with a more subjective measure (e.g., quality of life, VAS score) and evaluates the responsiveness and importance of changes in the subjective measure [3, 6] . Distribution-based methods involve statistical calculations of CID and have been assessed in various therapeutic areas [6] , including subjective measures of pain [7] . Because CIDs of abuse liability outcome measures have not yet been evaluated, one goal of this study was to determine CIDs for the subjective ratings of drug high in opioid abuse liability studies.
Abusers often tamper with (chew, crush, dissolve) extended-release (ER) opioid formulations to rapidly deliver high concentrations of opioids. To minimize risk of opioid abuse, manufacturers develop ER formulations that resist tampering. ALO-01, a novel oral capsule formulation of morphine, contains multiple pellets; each pellet contains morphine surrounded by an ER membrane and a core of naltrexone (NTX), an opioid antagonist [8, 9] . Under normal use, morphine is slowly released to control pain for 12-24 h, while NTX remains sequestered in the core. If the formulation is chewed or crushed, NTX is released from the core, reducing morphine's euphoric effects. Our second goal was to determine whether statistically significant reductions in drug high produced between morphine and ALO-01, and between altered and intact ALO-01, are clinically important, i.e., meet our estimated CID criteria for drug high in opioid liability studies.
Methods
We used anchor-and distribution-based methods to determine CIDs in drug high for opioid products and thereby predict a product's abuse liability post-marketing.
Dataset for CID calculation
Data from Comer [10] were used to establish CIDs in subjective ratings of drug high (Table 1) . Twelve heroin-dependent men received a single dose of 192 mg (n = 6) or 384 mg (n = 6) sustained-release depot NTX (Depotrex Ò ). All participants then received 0, 6.25, 12.5, 18.75, and 25 mg intravenous (IV) heroin. The entire heroin dose range was tested each week (1 dose tested each day). Subjective effects of heroin were evaluated using a VAS for ''I feel … high'' (0 mm: ''Not at all,'' to 100 mm: ''Extremely''). Ratings of ''feeling high'' were completely suppressed 1 week after injection of NTX 192 mg and then re-emerged 4 weeks later (Fig. 1) .
Differences in drug high over time (Weeks 1-4) and between NTX doses (192 mg vs. 384 mg) in subjects receiving heroin 25 mg were statistically significant (Fig. 1) ; we evaluated whether these statistically significant differences over time and in doses were CIDs (CID and CID Dose , respectively) using anchor-or distributionbased methods (described below).
Anchor-based methods
Two objective measures (break point and retention rate) served as anchors for subjective measure of drug high (Table 1) .
Break point
Data from Sullivan [12] were used to anchor ratings of drug high with break point (heroin dose at which the abuser prefers getting heroin over money, in this case, $20). Five heroin-dependent adults received a single 384 mg dose of sustained-release depot NTX (Depotrex Ò ), and the effects of various heroin doses (0, 6.25, 12.5, and 25 mg) were evaluated for 6 weeks. The entire dose range was tested each week (1 dose tested each day). A statistically significant difference in break point occurred between Weeks 1 and 4 (Fig. 2) ; therefore, break point was used as anchor for the CID Week1-4 in Comer [10] . The break point anchor was further justified by a meta-analysis of NTX studies [13] . CID clinically important difference, NTX naltrexone, VAS visual analog scale, MS morphine sulphate, IV intravenous, PO by mouth, IRMS immediate-release morphine sulphate Fig. 1 Subjective ratings. Ratings of drug high with heroin 25 mg as a function of week after administration of 192 mg (triangle) and 384 mg (square) depot NTX. Data points represent mean peak ratings (n = 6 per group). Data from Comer et al. [10] . NTX naltrexone, CID clinically important difference, VAS visual analog scale 
Retention rate
Data from Comer [11] were used to anchor ratings of drug high with the rates of retention in treatment. Sixty heroindependent adults were randomized to receive placebo, or 192 mg or 384 mg of sustained-release depot NTX (Depotrex Ò ) at the beginning of Weeks 1 and 5. The retention rate (percent of randomized subjects still present in the study) was used to evaluate NTX effectiveness. A statistically significant difference in retention rate was observed between 192 and 384 mg doses (Fig. 3) ; therefore, retention rate was used as anchor for the CID Dose in Comer [10] . The 95% confidence interval (CI) of the CID was calculated for both anchor-based methods.
Distributional methods
Studies ALO-01-07-205 and ALO-01-07-106 were used in the distribution-based analysis of CID (Table 1) .
ALO-01-07-205 (www.clinicalTrial.gov; No. NCT0075-1478). Thirty-two healthy, opioid-experienced, non-dependent adults were enrolled in a randomized, double-blind, crossover study with oral administration of immediate-release morphine sulfate (IRMS), crushed ALO-01, intact ALO-01, or placebo. Measurements of drug high (100-mm VAS) were used for CID evaluations.
ALO-01-07-106. Twenty-nine opioid-experienced, nondependent men were enrolled in a randomized, doubleblind, crossover study with IV administration of morphine sulphate (MS) alone, MS ? NTX, or placebo. The Drug Effects Questionnaire (DEQ) question, ''How high are you now?'' (on a 100-mm VAS) was the primary pharmacodynamic endpoint for CID evaluations.
Distributional approaches to clinical significance involve quantifying changes in the distribution of measure (e.g., drug high) upon intervention (e.g., administration of NTX). Usually, changes C0.5 standard deviation (SD) [14] or 1 standard error of the mean (SEM) [15] between 2 interventions are considered clinically meaningful. We used both pooled SD [14] and pooled SEM approaches [15] .
The pooled SD (S p ) for various conditions in ALO-01 studies used the formula:
, where n is sample size and s is variance. One-half of the pooled SD (CID Sp ) was then compared with the means for the pairwise comparisons of interest.
The pooled SEM method was adapted from Wyrwich [15] using the formula: s "
q , extended to compare several conditions. The process described above was used to calculate differences between group means using the pooled SEM to obtain CID SEM .
Analysis of ALO-01 clinical data
To determine whether the decreases in drug high scores observed with the NTX interventions in the 2 ALO-01 studies were clinically important, we compared the differences in VAS Drug High scores between the groups to the anchor-based calculated CIDs (CID Week1-4 and CIDDose ) and the distribution-based calculated CIDs (CID SEM and CID Sp ) at E max (maximum effect) for each condition.
We also compared the differences between groups to the upper 95% CI for anchor-based CIDs and to the lower 95% CI for distributional CIDs.
Results

CID calculations
Anchor-based calculations from Comer [10] yielded similar CIDs (overlapping CIs): CID Week1-4 was 10.17 mm (95% CI 3.00, 17.33; N = 5), and CID Dose was 8.83 mm (95% CI 1.14, 16.53; N = 60) ( Table 2) . Distributional methods using oral data also yielded similar CIDs (9.52 mm and 13.46 mm for SEM and S p methods, respectively) ( Table 2) . Distributional CIDs with IV data were somewhat smaller (SEM, 5.73 mm; S p , 8.54 mm). Table 2 ), indicating these differences are probably clinically important. These differences were also greater than the upper 95% confidence limits of both mean anchor-based CIDs, the most conservative limit.
The differences in mean VAS Drug High scores between groups (Table 3) were also greater than the CIDs calculated by distributional methods (8.54 and 5.73 mm; Table 2 ). The lower 95% CI limits of these mean differences (range = 17.73-79.33 mm) were all greater than the IV CIDs calculated by distributional methods (5.73 and 8.54 mm).
ALO-01-07-205 (PO)
Except for crushed versus intact ALO-01, all the mean differences in VAS Drug High scores (Table 3) were greater than both anchor-and distribution-based CIDs ( Table 2 ). All pairwise differences (except intact vs. crushed ALO-01) were greater than the upper 95% confidence limit of the anchor-based CIDs. Further, all lower 95% confidence limits for the mean between-group comparisons (Table 3) were greater than the distribution-based CIDs (Table 2) .
Discussion
This study aimed to determine whether statistically significant reductions in drug high produced by tampered ALO-01 versus comparators were clinically important. We first determined CIDs in drug high-the difference in VAS Drug High score that predicts the product's abuse liability postmarketing. Such novel CID analyses for drug high in abuse IV CID: CID calculated with data using IV administration (ALO-01-07-106)
CI confidence interval, CID clinically important difference, NTX naltrexone, S p one-half of the pooled standard deviation, SEM standard error of the mean, VAS visual analog scale, PO by mouth, IV intravenous liability studies help provide a criterion for determining a product's clinically significant abuse liability. We measured CID using anchor-and distribution-based approaches. Anchor-based CIDs ranged from 8.83 to 10.17 mm; distribution-based estimates from oral dosing were 9.52 and 13.46 mm (100-mm VAS). The results' similarity suggests that the distribution-based approach supports the findings from the anchor-based approach. Distributional CIDs with IV data were smaller (5.73 and 8.54 mm) because data from IV studies are less variable, leading to a smaller difference that can be considered clinically meaningful. Although anchor-based methods are generally preferred [6, 16] , distributional CID estimates are recommended when anchor-based estimates are unavailable.
We considered, but did not use, 2 other studies [9, 17] evaluating the abuse liability of NTX ? morphine. One study did not measure drug high [17] ; the other used multidimensional measures of drug high.
CIDs between IRMS and crushed or intact ALO-01 (Table 4 ) demonstrated that euphoria produced by crushed ALO-01 is clinically significantly less than euphoria produced by IRMS. Furthermore, because no CID existed between intact and crushed ALO-01 (Table 4) , abusers may not be interested in tampering with ALO-01. The results also suggest that ALO-01 has an IV abuse liability closer to placebo than to morphine.
The time to drug-induced euphoria (Table 5 ) dictates a drug's potential for abuse: Drugs with shorter time to euphoria have higher abuse potential [16] . Crushed ALO-01 had a longer time to euphoria (3.03 h) than IRMS (1.69 h), suggesting that crushed/chewed ALO-01 has a lower abuse potential than IRMS. Moreover, subjective effects produced by crushed ALO-01 (E max = 3.03 h) are delayed when compared with the peak of morphine (T max = 1.1 h), suggesting that NTX released from crushed ALO-01 attenuates morphine's euphoric effects.
Several considerations arise from this study. First, anchorbased CIDs were calculated from 2 studies using small sample sizes. Thus, CIDs from opioid studies with larger samples, other classes of abused drugs, or other subjective measures are recommended, to validate the present study. Second, the different populations for the anchor studies (heroin-dependent) and ALO-01 studies (non-dependent) may bias CID calculation. Third, injecting morphine plus NTX (as in the ALO-01 IV study) may not exactly mimic the crushing and IV administration of ALO-01.
The 8-10 mm differences in VAS Drug High are clinically important. Using this CID criterion, we found that intact or crushed ALO-01 has significantly lower oral and IV abuse liability than IR morphine formulations. However, The calculated differences between groups are provided in Table 3 ALO-01 extended-release morphine with sequestered naltrexone, C max plasma concentration to maximum subjective rating, E max maximum subjective rating, IRMS immediate-release morphine sulfate, SD standard deviation, T max time to maximum subjective rating, and VAS visual analog scale definitive evidence of the abuse deterrence of ALO-01 in the community has not yet been determined.
